Notably, after correction for the bias caused by the univariate analysis, elevated KIF11 (HR = 3.05, 95% CI 1.29–7.19, p = 0.01) and KIF14 (HR = 0.25, 95% CI 0.10–0.67, p = 0.006) immunointensities were able to predict the clinical endpoint (OS) independently of age at diagnosis, gender, tumor grade, clinical stage, pN, pT, PNI, and VI. Here, KIF14 is linked to neoplasm.